{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.17","spread":"2.17","upperLimit":"3.65","value":"2.8"},{"groupId":"OG001","lowerLimit":"1.84","spread":"1.84","upperLimit":"2.33","value":"1.9"}]}],"title":"VAS"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.97","spread":"1.97","upperLimit":"3.52","value":"2.8"},{"groupId":"OG001","lowerLimit":"1.84","spread":"1.84","upperLimit":"2.66","value":"1.9"}]}],"title":"HUI"}],"denoms":[{"counts":[{"groupId":"OG000","value":"478"},{"groupId":"OG001","value":"476"}],"units":"Participants"}],"description":"The EuroQol five dimension health questionnaire (EQ-5D-3L) assesses quality of life along 5 dimensions. Participants rate 5 aspects of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The summed score ranges from 3-15 with \"3\" corresponding to no problems and \"15\" corresponding to severe problems in the 5 dimensions. EQ-5D-3L also included an EQ visual analogue scale (VAS) that ranges between 100 (best imaginable health) and 0 (worst imaginable health). Decrease from baseline in EQ-5D-3L signifies improvement. Total index EQ-5D-3L summary score was weighted with a range of -0.594 (worst) to 1.0 (best). EQ-5D-3L also included an EQ health utilities index (HUI) where 1.00 indicated perfect health while a score of 0.00 indicated death. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date.","dispersionType":"95% Confidence Interval","groups":[{"description":"Subjects received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (\\>=) 60 kilogram (kg) or 8 mg based on the subject's body weight less than (\\<) 60 kg at baseline, orally, once daily (QD) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.","id":"OG000","title":"Lenvatinib"},{"description":"Participants received sorafenib 400 mg tablets, orally, twice daily (BID) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.","id":"OG001","title":"Sorafenib"}],"paramType":"MEDIAN","populationDescription":"The FAS included all participants who were randomized.","reportingStatus":"POSTED","timeFrame":"Baseline up to Off-Treatment Visit (approximately up to 3.8 years)","title":"Time to Clinically Meaningful Worsening of HRQoL Assessed Using EuroQol Five Dimension Health Questionnaire (EQ-5D-3L)","type":"SECONDARY","unitOfMeasure":"months"}